Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rare Disease Therapeutics
Pharma
Travere CEO Eric Dube to step down
Bradley Campbell, who led Amicus Therapeutics until its recent $4.8 billion acquisition by BioMarin, will become Travere's new CEO.
Angus Liu
Sep 22, 2026 10:10am
FDA approves Ultragenyx gene therapy after prior rejection
Sep 17, 2026 4:50pm
Alkermes’ Lumryz, from $2.4B Avadel buy, hits phase 3 mark in IH
May 12, 2026 11:45am
FDA to reconsider rejected cell therapy. Could uniQure be next?
May 7, 2026 10:40am
In another win for rare disease, Travere nabs FDA’s first FSGS nod
Apr 13, 2026 6:25pm
Fast-rising UCB scores FDA nod for rare disease drug Kygevvi
Nov 4, 2025 11:36am
